Clinical Trial Update: Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating liraglutide 3.0 mg as an adjunct to intensive behavior therapy for obesity in a non-specialist setting; study completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• liraglutide 3.0 mg (liraglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Metabolism and Nutrition Disorder, Obesity | Phase 3 | Status: COMPLETED | Results posted: 2019-07-30